Table 2.
Type and time to development of second primary malignancy
| Type of second primary malignancy | Patients n (% by total cohort) | Median time to SM (y) |
|---|---|---|
| IF-SPM | ||
| Colorectal | 4 (1.0) | 8.5 |
| Bladder | 6 (2.0) | 8.5 |
| Bone sarcoma (pubic) | 1 (0.3) | 14.2 |
| Total | 11 (3.0)∗ | 10.4 |
| OOF-SPM | ||
| Lung | 6 (2.0) | 8.5 |
| Esophagogastric | 2 (0.6) | 15.6 |
| Pancreas | 4 (1.3) | 7.6 |
| Renal | 4 (1.3) | 9.8 |
| Thyroid | 1 (0.3) | 9.1 |
| Leukemia/lymphoma/myeloma | 6 (2.0) | 11.1 |
| Melanoma | 7 (2.3) | 8.4 |
| Bone sarcoma (mandible) | 1 (0.3) | 15.7 |
| Total | 31 (9.3)∗ | 8.6 |
| Total patients | 38 (12.6)∗ | 8.8 |
Abbreviations: IF-SPM = in-field second primary malignancy; OOF-SPM = out-of-field second primary malignancy.
∗
Of note, 1 patient had 2 IF-SPM, 2 patients had both an IF- and OOF-SPM, 2 patients had 2 OOF-SPM, and 1 patient had an unknown SPM not categorized as IF or OOF.